Compare Stocks: AKBA, GERN, DSGN, and ANNX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKBA Akebia Therapeutics	$0.97 -0.9%	$1.13	$0.81 ▼ $3.20	$272.48M	0.19	8.76 million shs	8.35 million shs
ANNX Annexon	$4.87 +0.6%	$5.38	$2.10 ▼ $7.18	$923.25M	1.21	2.44 million shs	1.23 million shs
DSGN Design Therapeutics	$15.14 +0.7%	$14.12	$5.28 ▼ $17.25	$940.60M	1.66	554,668 shs	256,616 shs
GERN Geron	$1.57 +4.0%	$1.47	$1.04 ▼ $2.01	$970.14M	0.61	9.45 million shs	11.48 million shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKBA Akebia Therapeutics	-0.87%	+10.94%	-24.44%	+4.21%	-68.76%
ANNX Annexon	+0.62%	-2.01%	-9.31%	-7.94%	+137.56%
DSGN Design Therapeutics	+0.73%	+0.20%	+11.57%	+42.16%	+154.03%
GERN Geron	+3.97%	+3.97%	-3.68%	+34.19%	+12.14%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKBA Akebia Therapeutics	$0.97 -0.9%	$1.13	$0.81 ▼ $3.20	$272.48M	0.19	8.76 million shs	8.35 million shs
ANNX Annexon	$4.87 +0.6%	$5.38	$2.10 ▼ $7.18	$923.25M	1.21	2.44 million shs	1.23 million shs
DSGN Design Therapeutics	$15.14 +0.7%	$14.12	$5.28 ▼ $17.25	$940.60M	1.66	554,668 shs	256,616 shs
GERN Geron	$1.57 +4.0%	$1.47	$1.04 ▼ $2.01	$970.14M	0.61	9.45 million shs	11.48 million shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKBA Akebia Therapeutics	-0.87%	+10.94%	-24.44%	+4.21%	-68.76%
ANNX Annexon	+0.62%	-2.01%	-9.31%	-7.94%	+137.56%
DSGN Design Therapeutics	+0.73%	+0.20%	+11.57%	+42.16%	+154.03%
GERN Geron	+3.97%	+3.97%	-3.68%	+34.19%	+12.14%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AKBA Akebia Therapeutics	2.33	Hold	$3.75	284.73% Upside
ANNX Annexon	2.40	Hold	$15.14	210.94% Upside
DSGN Design Therapeutics	2.88	Moderate Buy	$16.50	8.98% Upside
GERN Geron	2.20	Hold	$4.00	154.78% Upside

Current Analyst Ratings Breakdown

Latest AKBA, GERN, DSGN, and ANNX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/1/2026	ANNX Annexon	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$10.00 ➝ $14.00
8/31/2026	AKBA Akebia Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/17/2026	AKBA Akebia Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/13/2026	ANNX Annexon	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Underperform ➝ Market Perform
8/11/2026	GERN Geron	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/7/2026	AKBA Akebia Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform	$1.00
8/6/2026	AKBA Akebia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/3/2026	AKBA Akebia Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/24/2026	GERN Geron	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/21/2026	ANNX Annexon	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Market Underperform
7/21/2026	ANNX Annexon	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Market Underperform	$3.00

(Data available from 9/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AKBA Akebia Therapeutics	$236.20M	1.14	N/A	N/A	$0.09 per share	10.83
ANNX Annexon	N/A	N/A	N/A	N/A	$0.98 per share	N/A
DSGN Design Therapeutics	N/A	N/A	N/A	N/A	$3.23 per share	N/A
GERN Geron	$183.88M	5.49	N/A	N/A	$0.34 per share	4.62

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AKBA Akebia Therapeutics	-$5.34M	-$0.11	N/A	N/A	N/A	-13.54%	-88.88%	-7.74%	11/9/2026 (Estimated)
ANNX Annexon	-$206.69M	-$1.16	N/A	N/A	N/A	N/A	-106.15%	-79.82%	11/9/2026 (Estimated)
DSGN Design Therapeutics	-$69.79M	-$1.18	N/A	N/A	N/A	N/A	-34.03%	-32.05%	11/4/2026 (Estimated)
GERN Geron	-$83.50M	-$0.11	N/A	26.17	N/A	-34.17%	-24.48%	-10.30%	11/4/2026 (Estimated)

Latest AKBA, GERN, DSGN, and ANNX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	ANNX Annexon	-$0.2388	-$0.28	-$0.0412	-$0.28	$6.50 million	N/A
8/5/2026	Q2 2026	AKBA Akebia Therapeutics	-$0.0420	-$0.02	+$0.0220	-$0.03	$48.85 million	$49.13 million
8/5/2026	Q2 2026	GERN Geron	-$0.0089	-$0.02	-$0.0111	-$0.02	$55.30 million	$57.48 million
8/3/2026	Q2 2026	DSGN Design Therapeutics	-$0.3443	-$0.32	+$0.0243	-$0.32	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AKBA Akebia Therapeutics	N/A	N/A	N/A	N/A	N/A
ANNX Annexon	N/A	N/A	N/A	N/A	N/A
DSGN Design Therapeutics	N/A	N/A	N/A	N/A	N/A
GERN Geron	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AKBA Akebia Therapeutics	0.99	1.43	1.35
ANNX Annexon	N/A	5.53	5.53
DSGN Design Therapeutics	N/A	18.86	18.86
GERN Geron	0.55	6.91	5.16

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AKBA Akebia Therapeutics	33.92%
ANNX Annexon	N/A
DSGN Design Therapeutics	56.64%
GERN Geron	73.71%

Insider Ownership

Company	Insider Ownership
AKBA Akebia Therapeutics	4.30%
ANNX Annexon	10.31%
DSGN Design Therapeutics	17.10%
GERN Geron	1.71%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AKBA Akebia Therapeutics	430	277.11 million	265.19 million	Optionable
ANNX Annexon	60	189.58 million	170.03 million	Optionable
DSGN Design Therapeutics	40	62.58 million	51.88 million	Optionable
GERN Geron	70	642.47 million	631.49 million	Optionable

AKBA, GERN, DSGN, and ANNX Headlines

Recent News About These Companies

Man Group plc Takes $892,000 Position in Geron Corporation $GERN

September 4 at 4:55 AM | marketbeat.com

Geron (NASDAQ:GERN) Stock Price Down 4.7% - What's Next?

September 3 at 2:24 PM | marketbeat.com

Did Geron Corporation Insiders Breach their Fiduciary Duties to Shareholders?

September 2 at 3:58 PM | prnewswire.com

Kuehn Law Encourages Investors of Geron Corporation to Contact Law Firm

September 2 at 1:36 PM | prnewswire.com

Geron (NASDAQ:GERN) Trading Up 7.1% - Should You Buy?

September 2 at 12:19 PM | marketbeat.com

Geron to Present at Upcoming Investor Conferences

September 2 at 8:00 AM | globenewswire.com

Moore Capital Management LP Makes New Investment in Geron Corporation $GERN

September 1, 2026 | marketbeat.com

BlackRock Inc. Makes New Investment in Geron Corporation $GERN

August 31, 2026 | marketbeat.com

Nantahala Capital Management LLC Buys Shares of 12,225,000 Geron Corporation $GERN

August 29, 2026 | marketbeat.com

J. Goldman & Co LP Makes New Investment in Geron Corporation $GERN

August 27, 2026 | marketbeat.com

Deutsche Bank AG Purchases New Position in Geron Corporation $GERN

August 26, 2026 | marketbeat.com

Geron Corporation $GERN Stake Raised by Bank of America Corp DE

August 26, 2026 | marketbeat.com

Edmond DE Rothschild Holding S.A. Buys New Holdings in Geron Corporation $GERN

August 21, 2026 | marketbeat.com

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 18, 2026 | globenewswire.com

Geron Corp.: Management's Plan Taking Shape As Competition Heats Up In Myelofibrosis

August 18, 2026 | seekingalpha.com

Geron’s RYTELO Drives Revenue as Trial Risks Linger

August 16, 2026 | tipranks.com

Geron (NASDAQ:GERN) Stock Price Down 5.2% - Here's Why

August 14, 2026 | marketbeat.com

Geron (NASDAQ:GERN) Shares Up 6.4% - Here's What Happened

August 11, 2026 | marketbeat.com

Geron Corporation $GERN Stake Raised by Renaissance Technologies LLC

August 10, 2026 | marketbeat.com

Geron (GERN) Is Up 14.7% After Issuing First RYTELO Revenue Guide And Narrowing Losses - Has The Bull Case Changed?

August 9, 2026 | finance.yahoo.com

Geron (GERN) Back In Focus As Fresh Guidance And Earnings Test Its Undervalued Narrative

August 9, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AKBA, GERN, DSGN, and ANNX Company Descriptions

Akebia Therapeutics NASDAQ:AKBA

$0.97 -0.01 (-0.87%)

As of 09/4/2026 04:00 PM Eastern

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Annexon NASDAQ:ANNX

$4.87 +0.03 (+0.62%)

As of 09/4/2026 04:00 PM Eastern

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.

Design Therapeutics NASDAQ:DSGN

$15.14 +0.11 (+0.73%)

As of 09/4/2026 04:00 PM Eastern

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.

Geron NASDAQ:GERN

$1.57 +0.06 (+3.97%)

As of 09/4/2026 04:00 PM Eastern

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AKBA, GERN, DSGN, and ANNX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AKBA, GERN, DSGN, and ANNX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AKBA, GERN, DSGN, and ANNX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AKBA, GERN, DSGN, and ANNX Company Descriptions

Akebia Therapeutics NASDAQ:AKBA

Annexon NASDAQ:ANNX

Design Therapeutics NASDAQ:DSGN

Geron NASDAQ:GERN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AKBA, GERN, DSGN, and ANNX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AKBA, GERN, DSGN, and ANNX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AKBA, GERN, DSGN, and ANNX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AKBA, GERN, DSGN, and ANNX Company Descriptions

Akebia Therapeutics NASDAQ:AKBA

Annexon NASDAQ:ANNX

Design Therapeutics NASDAQ:DSGN

Geron NASDAQ:GERN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools